brexit-istock-537519806_andrewlinscott

andrewlinscott / iStockphoto.com

16 August 2019Big PharmaSaman Javed

Pharma bodies sign NDAs with UK govt over no-deal Brexit plans

Several pharma bodies have signed non-disclosure agreements (NDAs) which prevent them from disclosing the UK government’s plans for a no-deal Brexit.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

No-deal Brexit could ‘irreparably’ harm NHS and delay drugs: BMA

3 September 2019 Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.

UK faces medicine shortages after no deal: leaked govt report

21 August 2019 A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.

EMA settles Brexit dispute; issues drug shortages guidance

8 July 2019 The European Medicines Agency has ended a Brexit legal dispute over its Canary Wharf, London headquarters.

More on this story

No-deal Brexit could ‘irreparably’ harm NHS and delay drugs: BMA

3 September 2019 Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.

UK faces medicine shortages after no deal: leaked govt report

21 August 2019 A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.

EMA settles Brexit dispute; issues drug shortages guidance

8 July 2019 The European Medicines Agency has ended a Brexit legal dispute over its Canary Wharf, London headquarters.

More on this story

No-deal Brexit could ‘irreparably’ harm NHS and delay drugs: BMA

3 September 2019 Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.

UK faces medicine shortages after no deal: leaked govt report

21 August 2019 A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.

EMA settles Brexit dispute; issues drug shortages guidance

8 July 2019 The European Medicines Agency has ended a Brexit legal dispute over its Canary Wharf, London headquarters.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?